Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Apellis Pharmaceuticals, Inc. Director's Dealing 2021

Feb 1, 2021

31417_dirs_2021-02-01_de397323-9e55-45f7-9c6f-63044d725b1c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-01-28

Reporting Person: Watson David O. (General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-28 Common Stock A 7500 Acquired 94387 Direct
2021-01-28 Common Stock A 1875 Acquired 96262 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-28 Stock Option (Right to Buy) $44.90 A 45000 Acquired 2031-01-27 Common Stock (45000) Direct
2021-01-28 Stock Option (Right to Buy) $44.90 A 11250 Acquired 2031-01-27 Common Stock (11250) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10000 Indirect

Footnotes

F1: This Restricted Stock Units grant will vest 25% annually over four years from grant date, subject to continued service.

F2: This Performance Unit grant will vest 25% annually over four years from grant date, subject to the satisfaction of a specified performance condition and continued service.

F3: The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F4: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F5: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.